Myelopathy secondary to spinal epidural lipomatosis. A case report.
Explore the source record for details and available documents.
Epidural Space↗
Biomedical subjects
F E Munschauer
Publications and source records attributed to F E Munschauer.
Eye movements induced by head rotation in unresponsive patients.
Eye movements induced by head rotation were studied in 6 patients in acute coma, 4 patients in a persistent vegetative state, and 6 healthy, alert control subjects. Results from control subjects suggest that the oculocephalic response in the supine position is principally a vestibulo-ocular reflex. A position-step rotation of the head produced an initial oppositely directed eye movement, followed by a drift of the eyes back toward midline with a negative exponential time course. The time constant of this drift was greater than or equal to 10 seconds in control subjects but less than or equal to 1.5 seconds in unconscious patients and less than or equal to 0.5 seconds in vegetative patients. The rapid drift back of the eyes in unresponsive patients implies dysfunction of reticular and, possibly, cerebellar connections; the rate of this drift may indicate the severity and extent of brain injury. Sinusoidal head rotation produced slow and quick phases of nystagmus in normal subjects. Quick phases were absent in patients in acute coma; although present in vegetative patients, the quick phases did not keep the eyes close to primary position, as was the case in control subjects.
Adult↗
Rationale for early treatment with interferon beta-1a in relapsing-remitting multiple sclerosis.
Disease-modifying therapies are now available for the treatment of relapsing-remitting multiple sclerosis (RR-MS). These drugs have transformed the management of RR-MS from simply treating symptomatic disease to providing effective but incomplete prophylaxis against further disease activity. Our ability to modify disease activity is limited to reducing exacerbations and delaying progression of disability. No intervention has yet been shown to reverse disability once it is established. To prevent disability, therapy should be initiated early in the course of the illness. The rationale for early treatment is as follows: (1) a high percentage of patients with clinically definite RR-MS progress from isolated attacks to neurologic impairment and then to disability within a short time; (2) survival in MS is directly related to disability, so delaying the onset of disability could be expected to influence survival; (3) interferon (IFN) beta-1a has been shown to slow the progression of disability when given to RR-MS patients with impairment or mild disability; and (4) magnetic resonance imaging studies indicate that MS patients frequently have evidence of central nervous system inflammation without overt clinical symptoms, and it has been postulated that treatment of subclinical disease as identified by magnetic resonance imaging may improve long-term outcome. IFN-beta reduces the number of new T2-weighted lesions, as well as the number and volume of gadolinium-enhanced lesions. Aggressive early treatment with IFN beta-1a is recommended, particularly for patients with risk factors suggesting an unfavorable prognosis.
Brain↗
Managing side effects of interferon-beta in patients with relapsing-remitting multiple sclerosis.
In separate clinical trials, two preparations of recombinant interferon (IFN)-beta, IFN beta-1a and IFN beta-1b, reduced exacerbation rates in relapsing-remitting multiple sclerosis (RR-MS). Further, IFN beta-1a slows the progression of disability in patients with RR-MS. Although they are effective in the treatment of MS, use of these drugs is associated with both class-specific and agent-specific side effects. Class-specific side effects include fever, chills, myalgias, arthralgias, and other flulike symptoms beginning 2 to 6 hours after injection and resolving within 24 hours of injection. Transient worsening of preexisting MS symptoms also occurs infrequently. Agent-specific side effects include injection-site reactions with IFN beta-1b. Simple management strategies can be used to minimize these reactions, including patient education; tailoring the dose and time of administration of IFN-beta; and prescribing appropriate combinations of acetaminophen, non-steroidal anti-inflammatory drugs, and steroids. Although side effects tend to diminish with treatment, successful management allows long-term administration of these drugs to achieve a reduction in disease activity and commensurate improvement in outcomes.
Depression↗